Catalyst Pharmaceuticals (CPRX) EPS Estimated At $-0.05; Cintas (CTAS)’s Sentiment Is 1.04

October 29, 2017 - By Dolores Ford

Analysts expect Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) to report $-0.05 EPS on November, 8.They anticipate $0.00 EPS change or 0.00% from last quarter’s $-0.05 EPS. After having $-0.05 EPS previously, Catalyst Pharmaceuticals Inc’s analysts see 0.00% EPS growth. The stock decreased 1.79% or $0.05 on October 27, reaching $2.75. About 613,365 shares traded or 31.83% up from the average. Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) has risen 267.48% since October 29, 2016 and is uptrending. It has outperformed by 250.78% the S&P500.

Cintas Corporation is a provider of corporate identity uniforms through rental and sales programs, as well as a well-known provider of related business services, including entrance mats, restroom cleaning services and supplies, carpet and tile cleaning services, first aid and safety services and fire protection services and products. The company has market cap of $16.11 billion. The Company’s divisions include uniform rental and facility services, and first aid and safety services. It has a 34.75 P/E ratio. The Company’s uniform rental and facility service segment offers services, which include rental and servicing of uniforms and other garments, including flame resistant clothing, mats, mops and shop towels, and other ancillary items.

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The company has market cap of $232.53 million. The Firm is focused on developing and commercializing therapies for people with rare debilitating diseases. It currently has negative earnings. The Firm has three drugs in development: Firdapse, CPP-109 and CPP-115.

Investors sentiment increased to 2.22 in Q2 2017. Its up 1.01, from 1.21 in 2017Q1. It increased, as 7 investors sold Catalyst Pharmaceuticals Inc shares while 11 reduced holdings. 24 funds opened positions while 16 raised stakes. 33.29 million shares or 34.73% more from 24.71 million shares in 2017Q1 were reported. Voya Mgmt Ltd Co holds 32,973 shares or 0% of its portfolio. Boothbay Fund Mngmt Ltd Liability Com has 68,970 shares for 0.04% of their portfolio. Bnp Paribas Arbitrage accumulated 7,498 shares. California Pub Employees Retirement Systems has invested 0% in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX). Geode Capital Mgmt Llc invested in 0% or 613,849 shares. Alliancebernstein Ltd Partnership holds 0% or 11,800 shares in its portfolio. Nationwide Fund Advisors invested in 40,137 shares or 0% of the stock. Barclays Public Limited Com reported 0% of its portfolio in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX). Citigroup Inc has 180 shares for 0% of their portfolio. State Of Wisconsin Board reported 0% in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX). Kennedy Capital Mngmt has 918,438 shares. Goldman Sachs Group Inc Inc reported 0% of its portfolio in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX). Royal Bankshares Of Canada reported 165,041 shares or 0% of all its holdings. Creative Planning has 10,681 shares for 0% of their portfolio. Moreover, Morgan Stanley has 0% invested in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX).

Among 5 analysts covering Catalyst Pharmaceuticals (NASDAQ:CPRX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Catalyst Pharmaceuticals had 8 analyst reports since April 26, 2016 according to SRatingsIntel. The stock of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) has “Buy” rating given on Friday, August 11 by H.C. Wainwright. The firm has “Buy” rating given on Wednesday, August 30 by Roth Capital. As per Wednesday, October 5, the company rating was upgraded by Piper Jaffray. The stock has “Buy” rating by Piper Jaffray on Monday, August 7. SunTrust maintained the shares of CPRX in report on Friday, September 1 with “Buy” rating. Roth Capital maintained Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) rating on Thursday, August 10. Roth Capital has “Buy” rating and $4.7500 target. The rating was upgraded by PiperJaffray on Wednesday, October 5 to “Overweight”. Piper Jaffray downgraded the shares of CPRX in report on Tuesday, April 26 to “Neutral” rating.

The stock increased 0.01% or $0.01 on October 27, reaching $151.56. About 375,886 shares traded. Cintas Corporation (CTAS) has risen 32.38% since October 29, 2016 and is uptrending. It has outperformed by 15.68% the S&P500.

Ratings analysis reveals 0 of Cintas’s analysts are positive. Out of 2 Wall Street analysts rating Cintas, 0 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $123.0 while the high is $130.0. The stock’s average target of $126.50 is -16.53% below today’s ($151.56) share price. CTAS was included in 2 notes of analysts from August 26, 2016. Macquarie Research initiated the stock with “Neutral” rating in Friday, August 26 report. The rating was maintained by Stifel Nicolaus on Tuesday, December 20 with “Hold”.

Lionstone Capital Management Llc holds 8.85% of its portfolio in Cintas Corporation for 138,000 shares. Junto Capital Management Lp owns 566,680 shares or 6.29% of their US portfolio. Moreover, Jasper Ridge Partners L.P. has 4.36% invested in the company for 644,715 shares. The United Kingdom-based Royal Bank Of Scotland Group Plc has invested 3.93% in the stock. Contravisory Investment Management Inc., a Massachusetts-based fund reported 74,327 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By :